Deals and developments in pharma outsourcing

By Staff Reporter

- Last updated on GMT

Related tags: Pharmaceutical industry, Pharmacology, New chemical entity, Gsk

While the summer* heat may slow other industries, the outsourcing sector keeps on moving. Oustourcing-pharma rounds up the key developments, featuring LyoTechnica and AspenTech

Lyophilisation cycle development in under 60 days

Lyophilisation and liquid form contractor LyoTechnica has launched a new contract drug development services for injectable pharmaceuticals.

The company said that the new unit will offer both analytical and formulation development as well as sterile stability batches and stability testing batch manufacturing services.

The CUS firm claims to be able to complete “typical” lyophilisation cycle development in less than sixty days, which makes the service ideal with resource limited clients according to CEO Glenn Wicks Jr.

We work with pharmaceutical companies with limited resources as well as larger firms needing additional resources applied quickly to a project. Our framework allows for cost-effective and efficient development.”

AspenTech lands Big Pharma customers

US software firm AspenTech says deals with UK majors GlaxoSmithKline (GSK) and AstraZeneca demonstrate utility of aspenOne in pharmaceutical industry process optimisation.

The company said that its solubility modeling technology provides "Quality by Design" (QbD) capabilities that help drug manufacturers comply with the latest industry regulatory initiatives.

AspentTech cited GSK, a recent addition to its customer base, as an example of aspenOne’s drug industry utility.

It explained that GSK has been able to thoroughly understand the solubility properties of new chemical entities (NCE) to assess risks and improve confidence during the development of new pharmaceuticals.

This claim was supported by GSK’s Stephen Carino who said: "In our high-throughput screening workflow, we have utilized NRTL-SAC in Aspen Properties to predict the equilibrium solubility of the drug in single- and multi-component solvent systems.

This rational solvent selection coupled with the systematic screening approach has allowed us to assess risk around solid forms and improve our confidence in the robustness of the API processes​."

*Outsourcing-pharma hopes readers in the Southern hemisphere are enjoying the winter too.

Related news

Show more

Related products

show more

Using SDTM, ADaM, and SEND

Using SDTM, ADaM, and SEND

Formedix | 09-Nov-2022 | Technical / White Paper

This article gives an overview of SDTM, ADaM, SEND and ARM, and discusses how these CDISC standards fit in with the wider clinical trial process, and how...

How to design an effective CRF

How to design an effective CRF

Formedix | 10-Oct-2022 | Technical / White Paper

CRFs and eCRFs are used for gathering patient data during clinical trials. They play a crucial role in helping to assess the safety and efficacy of clinical...

The Complexities of Ophthalmic Drug Development

The Complexities of Ophthalmic Drug Development

Altasciences | 04-Oct-2022 | Technical / White Paper

Ophthalmic drug development comes with a unique set of challenges that can be mitigated by working with an end-to-end solution provider with regulatory...

Because When It's On the Line... Capability Matters.

Because When It's On the Line... Capability Matters.

Baxter BioPharma Solutions | 01-Oct-2022 | Product Brochure

Baxter’s BioPharma Solutions business supports leading pharmaceutical companies in meeting their commercialization objectives by providing scientific expertise,...

Related suppliers

Follow us


View more